LAWRENCE, Mass., March 13, 2018 /PRNewswire/ -- NxStage Medical,
Inc. (Nasdaq: NXTM), a leading medical technology company focused
on advancing renal care, announced new findings further
demonstrating the benefits of home hemodialysis with the NxStage®
System One™, including on-site hemodialysis at skilled nursing
facilities, solo home hemodialysis, and more frequent home
hemodialysis. The collection of data was presented at the recent
Annual Dialysis Conference (ADC) in Orlando, Florida.
"Our continuing research shows that more frequent home
hemodialysis is a clinically differentiated therapy," said
Joe Turk, President, NxStage
Medical, Inc. "Expansion of home hemodialysis in patient
populations that have lacked access holds great potential to
improve population outcomes."
On-Site Hemodialysis in Skilled Nursing Facilities:
Eric Weinhandl, PhD, MS, NxStage
Clinical Epidemiologist and Adjunct Assistant Professor at the
University of Minnesota, presented a
study of hospitalization and related Medicare expenditures in the
roughly 8,000 nursing home residents per year who initiated
dialysis. The study found that these patients were predominantly
elderly, spent 44 days per year in the hospital, and accumulated
over $38,000 in Medicare payments per
year for inpatient care.
"With an aging population, the number of nursing home residents
needing dialysis is expected to grow," said Dr. Weinhandl. "Using
the NxStage System One to provide more frequent and on-site
dialysis may help to improve quality of life in nursing home
residents and reduce hospitalizations,1,2 thereby
lowering associated Medicare expenditures."
Solo Home Hemodialysis:
Another abstract illustrated findings from the NxStage patient
preference survey that supported FDA clearance of the NxStage
System One for solo home hemodialysis. The findings showed that
within 32 subgroups, current home hemodialysis patients would
prefer solo home hemodialysis over in-center hemodialysis, even if
risk of death were significantly elevated on solo home
hemodialysis.
More Frequent Home Hemodialysis:
NxStage researchers also presented new data that were collected
with its remote patient management system, Nx2me Connected Health®,
and showed that patients on more frequent home hemodialysis had
lower risk of intradialytic hypotension than patients on
conventional in-center hemodialysis.
"Data consistently show that more frequent home hemodialysis has
cardiovascular benefits," said Dr. Weinhandl. "The therapy may be
especially useful in settings with historically poor clinical and
economic outcomes, such as nursing homes."
Full abstracts can be read online at
http://annualdialysisconference.org/abstracts/.
Visit www.NxStage.com for more information about therapy options
with the NxStage System One.
The NxStage System One is a prescription device and, like all
medical devices, involves some risks. The risks associated with
hemodialysis treatments in any environment include, but are not
limited to, high blood pressure, fluid overload, low blood
pressure, heart-related issues, and vascular access complications.
The medical devices used in hemodialysis therapies may add
additional risks including air entering the bloodstream, and blood
loss due to clotting or accidental disconnection of the blood
tubing set.
A trained and qualified patient may dialyze alone, without a
care partner present (solo home hemodialysis), provided the patient
and physician agree that solo home hemodialysis is appropriate.
Certain risks associated with hemodialysis treatment are increased
when performing solo home hemodialysis because no one is present to
help the patient respond to health emergencies. If patients
experience needles coming out, blood loss, or very low blood
pressure during solo home hemodialysis, they may lose consciousness
or become physically unable to correct the health emergency. Losing
consciousness or otherwise becoming impaired during any health
emergency while alone could result in significant injury or death.
Additional ancillary devices and training are required when
performing solo home hemodialysis. Patients should consult with
their physician to understand the risks and responsibilities
associated with home and/or more frequent hemodialysis, and
solo home hemodialysis using the NxStage System One. Additionally,
the reported benefits of home and/or more frequent hemodialysis may
not be experienced by all patients. Patients and providers are
encouraged to contact their state regulators to discuss
state-specific regulations that may impact dialysis in the skilled
nursing facility setting.
About the NxStage System One
The NxStage System One is the first and only truly portable
hemodialysis system cleared specifically by the FDA for home
hemodialysis, home nocturnal hemodialysis and solo home
hemodialysis. Its simplicity and revolutionary size (just over a
foot tall) are intended to allow convenient use in patients' homes
and give patients the freedom to travel with their therapy. When
combined with the NxStage PureFlow SL Dialysis Preparation System,
patients are able to further simplify, using ordinary tap water to
create dialysis fluid on demand. Unlike conventional hemodialysis
systems, the System One requires no special infrastructure to
operate. Under the guidance of their physician, patients can use
the NxStage System One, with their trained partners (or for
patients prescribed to receive solo dialysis, alone), where, how
and when it best meets their needs, including while they are
sleeping - at home or on vacation and at a medically appropriate
treatment frequency. In addition, NxStage's Nx2me Connected Health
platform collects important NxStage System One and patient
information for flexible viewing, monitoring and reporting that may
improve patient management and patient retention, as well as
simplify alternative site care. www.nxstage.com.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical
technology company, headquartered in Lawrence, Massachusetts, USA, that develops,
manufactures and markets innovative products for the treatment of
ESRD and acute kidney failure. NxStage also has established a small
number of dialysis clinics. For more information on NxStage and its
products and services, please visit the Company's websites at
www.nxstage.com and www.nxstagekidneycare.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors including those that are
discussed in NxStage's filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the year
ended December 31, 2017. NxStage is
under no obligation to (and expressly disclaims any such obligation
to) update or alter its forward-looking statements, whether as a
result of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
1Cornelis T, Kotanko P, Goffin E, van der Sande FM,
Kooman JP, Chan CT.
Intensive hemodialysis in the (nursing) home: the bright side of
geriatric ESRD
care? Semin Dial. 2012
Nov-Dec;25(6):605-10. doi: 10.1111/sdi.12011.
2Yang A, Lee WY, Hocking K. Survival comparison of
daily home hemodialysis vs.
conventional in the nursing home setting. Nephrol News Issues.
2015
Feb;29(2):25-7, 30-1.
View original content with
multimedia:http://www.prnewswire.com/news-releases/seven-unique-nxstage-abstracts-presented-during-the-38th-annual-dialysis-conference-300612593.html
SOURCE NxStage Medical, Inc.